Objective To investigate the efficacy and safety of lobaplatin in promoting liver wound healing following hepatectomy for patients with primary hepatocellular carcinoma. Methods From January 2019 to June 2024， 120 patients with primary hepatocellular carcinoma （HCC） at CNLC stages Ia to IIa were randomly divided into an observation group （n = 60） and a control group （n = 60）. The observation group underwent hepatectomy and received lobaplatin application on the liver wound during surgery， while the control group underwent hepatectomy alone without lobaplatin application. All patients were followed up for 66 months. Postoperative levels of ALT， AST， blood creatinine， white blood cells， and platelets were compared between the two groups. Additionally， the incidence of hemorrhage and bile leakage was compared， as well as the recurrence-free survival time after surgery. Results There were no significant differences between the two groups in terms of postoperative ALT， AST， blood creatinine， white blood cell count， or platelet levels（P > 0.05）. Additionally， no significant differences were observed in the incidence of postoperative hemorrhage and bile leakage between the two groups（P > 0.05）. However， a significant difference was noted in recurrence-free survival time between the groups（P > 0.05）， with the recurrence-free survival curve indicating a higher recurrence-free survival rate in the observation group compared to the control group（P > 0.05）. Conclusions Lobaplatin application for liver wound healing in hepatectomy of patients with primary hepatocellular carcinoma represents a feasible， safe， and effective adjuvant therapy. This approach can decrease the early recurrence rate in patients with early-stage primary hepatocellular carcinoma， making it worthy of clinical promotion.